June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Currently proposed mechanisms and remaining unknowns for pharmacological treatments, with a focus on low dose atropine eye drops
Author Affiliations & Notes
  • Regan Ashby
    Faculty of Science and Technology, University of Canberra, Canberra, Australian Capital Territory, Australia
    Research School of Biology, Australian National University, Canberra, Australian Capital Territory, Australia
  • Footnotes
    Commercial Relationships   Regan Ashby University of Canberra, Code P (Patent)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 18. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Regan Ashby; Currently proposed mechanisms and remaining unknowns for pharmacological treatments, with a focus on low dose atropine eye drops. Invest. Ophthalmol. Vis. Sci. 2023;64(8):18.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Presentation Description : Several pharmacological interventions have been shown to slow myopia progression (atropine, pirenzepine and 7-MX). However, their site and mechanism of action is not well understood, which can limit our ability to comprehensively assess their efficacy and safety profiles or to develop novel variants to increase treatment outcomes and reduce off-target effects. This talk will outline some of the gaps in our knowledge, with a particular focus on atropine (due to its effectiveness and widespread use).

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×